ReviewGeneral thoracic and cardiovascular surgery2026
A meta-analysis of cisplatin-based versus carboplatin-based adjuvant chemotherapy for completely resected non-small cell lung cancer.
Review in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative considerations and single-case feasibility claims in subcostal single-port robotic resection of a posterior mediastinal tumor in an infant.General thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin-based adjuvant chemotherapy is the standard of care for patients with completely resected non-small cell lung cancer (NSCLC). However, carboplatin-based regimens are often selected in clinical practice for patients considered unsuitable for cisplatin, although evidence regarding their long-term survival outcomes remains limited.
methodsWe conducted a meta-analysis to compare survival outcomes between cisplatin-based and carboplatin-based adjuvant chemotherapy in patients with completely resected NSCLC. PubMed and the Cochrane CENTRAL database were searched for relevant studies published up to April 7, 2026. Eligible studies included randomized and observational studies reporting hazard ratios (HRs) for overall survival (OS) and/or recurrence-free survival (RFS).
resultsA total of eight studies involving 2269 patients were included. The pooled HRs for OS and RFS indicated no significant differences between the two regimens (OS: HR, 1.08; 95% CI 0.92-1.26; RFS: HR, 0.92; 95% CI 0.71-1.20). A sensitivity analysis limited to randomized controlled trials also demonstrated no significant differences between the two regimens (OS: HR, 0.95; 95% CI 0.60-1.51; RFS: HR, 0.96; 95% CI 0.59-1.58).
conclusionsCarboplatin-based adjuvant chemotherapy may be considered as an alternative in cisplatin-unfit patients with completely resected NSCLC.
Indexed as
Identifiers
42599571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.